Testing low-dose aspirin to reduce heart and blood vessel events after brain bleeding
Compares low-dose aspirin with a placebo in adults who survived a brain bleed.
Plain-language title generated from the registry record
Registry title: Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage
Key facts
- Where
- Belagavi, Bhubaneswar, Bikaner, Coimbatore, Delhi, Farīdkot, Guntur, Guwahati, Hyderabad, Jaipur, Kākināda, Kochi, Kolkata, Kota, Lucknow, Mumbai, Nellore, New Delhi, Patna, Pune, Raebareli, Ranchi, Tezpur, Thiruvananthapuram, Varanasi, and Vellore, IndiaSee the 33 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07243704, who can take part
Where in India
- KLE's Dr. Prabhakar Kore Hospital & Medical Research CentreBelagavi, IndiaTaking people
- All India Institute of Medical SciencesBhubaneswar, IndiaTaking people
- PBM HospitalBikaner, IndiaTaking people
- KG Hospital and Post Graduate Medical Institute CoimbatoreCoimbatore, IndiaTaking people
- St Stephen's HospitalDelhi, IndiaTaking people
- Guru Gobind Singh Medical College and HospitalFarīdkot, IndiaTaking people
- Dr Ramesh Cardiac and Multispecialty HospitalGuntur, IndiaTaking people
- Government General HospitalGuntur, IndiaTaking people
- Lalitha Super Specialty HospitalGuntur, IndiaTaking people
- All India Institute of Medical ScienceGuwahati, IndiaTaking people
- Apollo Excelcare HospitalsGuwahati, IndiaTaking people
- KIMS-Sunshine HospitalsHyderabad, IndiaTaking people
- Renova Institute of Neurological Sciences (RINS); Renova Century HospitalHyderabad, IndiaTaking people
- Santokba Durlabhji Memorial HospitalJaipur, IndiaTaking people
- Government General HospitalKākināda, IndiaTaking people
- Amrita Institute for Medical Sciences and Research CenterKochi, IndiaTaking people
- Bangur Institute of NeurosciencesKolkata, IndiaTaking people
- Jaiswal Hospital and Neuro InstituteKota, IndiaTaking people
- King George's Medical UniversityLucknow, IndiaTaking people
- Sanjay Gandhi Postgraduate Institute of Medical SciencesLucknow, IndiaTaking people
- P. D. Hinduja Hospital and Medical Research CentreMumbai, IndiaTaking people
- Narayana Medical College and HospitalNellore, IndiaTaking people
- All India Institute of Medical ScienceNew Delhi, IndiaTaking people
- Institute of Human Behaviour and Allied SciencesNew Delhi, IndiaTaking people
- All India Institute of Medical SciencePatna, IndiaTaking people
- Bharati Vidyapeeth DTU Medical CollegePune, IndiaTaking people
- All India Institute of Medical SciencesRaebareli, IndiaTaking people
- Rajendra Institute of Medical SciencesRanchi, IndiaTaking people
- Baptist Christian HospitalTezpur, IndiaTaking people
- Government Medical College TrivandrumThiruvananthapuram, IndiaTaking people
- Sree Chitra Tirunal Institute for Medical Sciences and TechnologyThiruvananthapuram, IndiaTaking people
- Institute of Medical Sciences of the Banaras Hindu University (BHU)Varanasi, IndiaTaking people
- Christian Medical College VelloreVellore, IndiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Christian Medical College and Hospital, Ludhiana, India
- Trial code
- NCT07243704
- Record updated
- 24 September 2026
- Original description
BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of the trial for preventing MACE. Recruitment duration is for 2.5 years. The duration of the medication and follow-up will vary based on recruitment timeline. If recruited during the first year of the trial, the patient will take the medication for three years or until the trial ends or an event occurs, with a matching follow-up period. If recruited towards the end of the trial, he/she will take the medication for six months and be followed up for the same duration. The trial's follow-up duration is three years. The patients will be recruited for 2.5 years, and the last recruit will have a minimum follow-up of six months. No new patients will be recruited within the last six months of the trial, but all the patients will be followed up until the end of the trial.Read full original descriptionShow less
Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage.
BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of the trial for preventing MACE. Recruitment duration is for 2.5 years. The duration of the medication and follow-up will vary based on recruitment timeline. If recruited during the first year of the trial, the patient will take the medication for three years or until the trial ends or an event occurs, with a matching follow-up period. If recruited towards the end of the trial, he/she will take the medication for six months and be followed up for the same duration. The trial's follow-up duration is three years. The patients will be recruited for 2.5 years, and the last recruit will have a minimum follow-up of six months. No new patients will be recruited within the last six months of the trial, but all the patients will be followed up until the end of the trial.
Inclusion: Age ≥18 years; First-ever Intracerebral Haemorrhage; Presenting ≥24 hrs up to 3 months of stroke symptoms confirmed by brain imaging; CT /MRI confirming Intracerebral Haemorrhage; Alive ≥24 hours after non-traumatic ICH.
Exclusion: Taking any antiplatelet or anticoagulant therapy 15 days prior to randomization; ICH is known to be due to trauma, a structural cause (e.g., aneurysm, arteriovenous malformation, cerebral cavernous malformation, venous thrombosis, or tumour), or haemorrhagic transformation of cerebral infarction; Glasgow coma score ≤5; Women pregnant, breastfeeding, childbearing potential, and not using contraceptives; Enrolled in any other clinical trial; Sick or compromised patients with life expectancy of less than a year; Geographical or other factors that prohibit long-term follow-up.